Wuhan Keqian Biology Co. Ltd. Class A

As of June 30, 2026, Wuhan Keqian Biology Co. Ltd. Class A carries a market capitalization of 5.64B, placing it among publicly traded companies globally. Its enterprise value stands at 3.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Wuhan Keqian Biology Co. Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Wuhan Keqian Biology Co. Ltd. Class A has 466.13M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Wuhan Keqian Biology Co. Ltd. Class A maintains a current ratio of 7.82, meaning it holds 7.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Wuhan Keqian Biology Co. Ltd. Class A recorded 26.25M in income tax expense.

As of the close on October 23, 2026, Wuhan Keqian Biology Co. Ltd. Class A's stock has declined approximately 29.80% over the past 52 weeks. The 50-day moving average sits at 12.58, while the 200-day moving average is 14.05.

As of June 30, 2026, Wuhan Keqian Biology Co. Ltd. Class A holds 1.85B in cash and equivalents against 6.59M in total debt, resulting in a net debt position of -169.96M. Total book value stands at 4.03B, with working capital of 2.64B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.